Pacific Biomarkers, Inc. to Host Webinar on Latest Developments in Biomarkers for Metabolic Syndrome on March 2

SEATTLE, WA--(Marketwire - February 17, 2011) - Pacific Biomarkers, Inc. (PBI) (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, will host a webinar titled “Biomarkers of Metabolic Syndrome in Clinical Trials” on Wednesday, March 2 at 11:00 am PST.

During the webinar, PBI scientists will discuss the latest developments in biomarkers for metabolic syndrome. The topics will include: 1) Pre-analytical and analytical concerns regarding gut and incretin hormones, 2) dysfunctional HDL biomarkers in metabolic syndrome, and 3) kidney injury markers and their usefulness in diabetic nephropathy. The webinar is aimed at scientists and physicians involved in drug development, with a focus on biomarker selection for clinical trials.

Three PBI senior scientists will speak during the webinar: Amar A. Sethi MD, PhD, Vice President Research and Development; Timothy Carlson, PhD, RD, NRCC, Laboratory Director/Senior Director of Biomarker Innovation; and Dorota Schranz, PhD, Director Biomarker Development & Validations.

Dr. Sethi’s research has focused on the identification and characterization of mutations affecting atherosclerotic cardiovascular diseases and, more recently, on cholesterol metabolism, with special emphasis on the function of HDL in the reverse cholesterol transport pathway and development of HDL raising therapies, including the study of apolipoprotein-AI mimetic peptides in animal models of atherosclerosis. Currently Dr. Sethi is focusing on the development of novel and innovative biomarkers to elucidate the role of HDL function in patients with ischemic heart disease.

Dr. Carlson has broad training and experience in basic and clinical sciences. He has received grant research awards from the National Institutes of Health, American Blood Systems Research Foundation, American Association of Blood Banks, and the American Heart Association. Dr. Carlson has published more than 75 research papers, chapters, and abstracts in the areas of nutrition, chronic disease, and hemostasis. He is a registered clinical chemist and dietitian, and he holds a PhD in biochemistry.

Dr. Schranz has more than 15 years of experience in both basic and clinical research with expertise in clinical biochemistry, endocrinology and immunology. Her academic research focused on understanding the etiology of diabetes mellitus and assay development for early diagnosis of DM. She has published research articles, chapters and abstracts primarily in the area of diabetes and development of diagnostic assays.

To participate in the webinar, please visit the following link:
https://presentations.inxpo.com/Shows/DNM/3-11/PacificBioMarkers/Registration/DNMRegBioMeta.html

About Pacific Biomarkers, Inc. (PBI)
Established in 1989, PBI provides biomarker laboratory services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, inflammation, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing. PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC.” For more information about PBI, visit the company’s web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company’s biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2010).